EGFR and non-small cell lung carcinoma: The phase-3, randomized, open-label, ARCHER 1050 trial demonstrated that first-line dacomitinib significantly improved progress-free survival (PFS) and overall survival (OS) compared with gefitinib in patients with EGFR mutation-positive advanced NSCLC (11).